RT Journal Article
T1 Dupilumab Improves Skin Barrier Function in Adults with Atopic Dermatitis: A Prospective Observational Study.
A1 Montero-Vilchez, Trinidad
A1 Rodriguez-Pozo, Juan-Angel
A1 Diaz-Calvillo, Pablo
A1 Salazar-Nievas, Maria
A1 Tercedor-Sanchez, Jesús
A1 Molina-Leyva, Alejandro
A1 Arias-Santiago, Salvador
K1 atopic dermatitis
K1 dupilumab
K1 skin barrier
K1 transepidermal water loss
AB Epidermal barrier dysfunction plays an important role in atopic dermatitis (AD). The difficulty of objectively assessing AD severity and the introduction of new biologicals into clinical practice highlight the need to find parameters to monitor clinical outcomes. The aim of this study is to evaluate the impact of dupilumab on skin barrier function and compare it with other treatments in patients with AD. A prospective observational study was conducted in adults with AD treated with topical corticosteroids (TCS), cyclosporine, or dupilumab. The main outcome measures after 16 weeks of treatment were Eczema Area and Severity (EASI)-50 (50% improvement in EASI), and transepidermal water loss (TEWL)-50 (50% improvement in TEWL). Forty-six patients with AD were included in the study. The proportion of patients who achieved EASI-50 at week 16 was significantly higher in patients receiving dupilumab (81.8% vs. 28.6% vs. 40%, p = 0.004). In eczematous lesions, TEWL decreased in patients receiving dupilumab (31.02 vs. 12.10 g·h−1·m−2, p
PB MDPI AG
SN 2077-0383
YR 2022
FD 2022-06-08
LK http://hdl.handle.net/10668/21295
UL http://hdl.handle.net/10668/21295
LA en
NO Montero-Vilchez T, Rodriguez-Pozo JA, Diaz-Calvillo P, Salazar-Nievas M, Tercedor-Sanchez J, Molina-Leyva A, et al. Dupilumab Improves Skin Barrier Function in Adults with Atopic Dermatitis: A Prospective Observational Study. J Clin Med. 2022 Jun 10;11(12):3341.
DS RISalud
RD Apr 7, 2025